Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).

Alessandra Narcisi,Mario Valenti,Luigi Gargiulo,Luciano Ibba,Fabrizio Amoruso,Giuseppe Argenziano,Federico Bardazzi,Martina Burlando,Carlo Giovanni Carrera,Giovanni Damiani,Paolo Dapavo,Valentina Dini,Chiara Franchi,Giampiero Girolomoni,Claudio Guarneri,Francesco Loconsole,Francesca Sampogna,Massimo Travaglini, Piergiorgio Malagoli,Antonio Costanzo

Journal of the European Academy of Dermatology and Venereology : JEADV（2023）

引用 15|浏览36

暂无评分

摘要

Our data suggest that the efficacy of tildrakizumab for plaque psoriasis in 'real-life' clinical practice is comparable with Phase 3 clinical trials with higher percentages of patients achieving complete skin clearance (PASI 100) at Weeks 16, 28 and 52.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要